Why the IV-to-subcutaneous gap is not a technicality For many peptides, moving from IV to subcutaneous changes the pharmacokinetics modestly a slower rise, a lower peak, decent bioavailability
When comparing these results with the results of the STEP-1 trial for Wegovy, we see that these medications are very similar in effectiveness
J Clin Endocrinol Metab 85:35753581 Deacon CF, Danielsen P, Klarskov L et al
This is fundamentally different from the injection site profile of tirzepatide or semaglutide , which generally produce minimal injection site reactions
Zepbound vs Wegovy Cost Comparison Cost is a major factor for many people
For patients with adequate baseline B status, injections provide minimal weight loss benefit on their own